Internal Medicine Alert – April 15, 2013
April 15, 2013
View Issues
-
Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
Colchicine, in addition to statins and other standard secondary prevention therapies, appeared effective for the prevention of cardiovascular events in patients with stable coronary disease. -
Not Everything That Can be Counted Counts!
As a federal program rolls out to award providers with incentives for achieving meaningful use in electronic health records, wide measure-by-measure variation can jeopardize the validity of electronic reporting. -
Rapid Identification of Gastro Pathogens Directly from Stool
On January 14, 2013, the FDA approved a device allowing detection of multiple gastrointestinal pathogens from a single sample of feces.1 -
Sex, Lies, and Technology
The Internet age has brought all kinds of conveniences and apps for your smart phone, from the popular app GRINDR (allowing you a speedy hookup with the nearest sexually available individual) to the newest MedXSafe, which allows you to literally bump phones and share confidential STD and HIV info before you bump into bed. -
Pharmacology Update: Regorafenib Tablets (Stivarga®)
An oral multikinase inhibitor has been approved by the FDA for treatment of metastatic colorectal cancer as well as advanced gastrointestinal stromal tumors (GIST). Regorafenib is marketed by Bayer HealthCare Pharmaceuticals as Stivarga. -
Clinical Briefs
Special Subgroups in Hypertension: Obese Hypertensives; Selection Criteria for Lung Cancer Screening; Extended Treatment of VTE with Dabigatran vs Warfarin -
ECG Review: RBBB with Acute STEMI?
The ECG shown above was obtained from a 62-year-old man who presented to the emergency department with a history of several presyncopal episodes in recent months. His ECG was diagnosed as showing acute anterior ST elevation myocardial infarction (STEMI). Do you agree? What treatment is indicated? -
Pharmacology Watch: Is This the End of the Road for Calcium Supplementation?
Calcium supplementation in women; type 2 diabetes treatments and pancreatitis risk; treating chronic idiopathic urticaria; rivaroxaban and VTE; and FDA actions.